COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy
Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with sev...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.961027/full |
| _version_ | 1811282741174468608 |
|---|---|
| author | Mansoor Khaledi Fatemeh Sameni Sheida Yahyazade Maedeh Radandish Parviz Owlia Nader Bagheri Hamed Afkhami Mohamad Mahjoor Zahra Esmaelpour Maryam Kohansal Farzad Aghaei |
| author_facet | Mansoor Khaledi Fatemeh Sameni Sheida Yahyazade Maedeh Radandish Parviz Owlia Nader Bagheri Hamed Afkhami Mohamad Mahjoor Zahra Esmaelpour Maryam Kohansal Farzad Aghaei |
| author_sort | Mansoor Khaledi |
| collection | DOAJ |
| description | Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors. |
| first_indexed | 2024-04-13T01:58:01Z |
| format | Article |
| id | doaj.art-3fdc51d375f24f8aa869a960cd9d96e2 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-13T01:58:01Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-3fdc51d375f24f8aa869a960cd9d96e22022-12-22T03:07:42ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-08-01910.3389/fmed.2022.961027961027COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategyMansoor Khaledi0Fatemeh Sameni1Sheida Yahyazade2Maedeh Radandish3Parviz Owlia4Nader Bagheri5Hamed Afkhami6Mohamad Mahjoor7Zahra Esmaelpour8Maryam Kohansal9Farzad Aghaei10Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, IranDepartment of Microbiology, Faculty of Medicine, Shahed University, Tehran, IranDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranMolecular Microbiology Research Center, Faculty of Medicine, Shahed University, Tehran, IranCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranShahed University, Tehran, IranDepartment of Immunology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IranReference Laboratory for Bovine Tuberculosis, Razi Vaccine and Serum Research Institute, Karaj, IranDepartment of Medical Biotechnology, Fasa University of Medical Sciences, Fasa, IranCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, IranRecent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors.https://www.frontiersin.org/articles/10.3389/fmed.2022.961027/fullCOVID-19JAK inhibitorsbaricitinibpacritinibruxolitinibtofacitinib |
| spellingShingle | Mansoor Khaledi Fatemeh Sameni Sheida Yahyazade Maedeh Radandish Parviz Owlia Nader Bagheri Hamed Afkhami Mohamad Mahjoor Zahra Esmaelpour Maryam Kohansal Farzad Aghaei COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy Frontiers in Medicine COVID-19 JAK inhibitors baricitinib pacritinib ruxolitinib tofacitinib |
| title | COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy |
| title_full | COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy |
| title_fullStr | COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy |
| title_full_unstemmed | COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy |
| title_short | COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy |
| title_sort | covid 19 and the potential of janus family kinase jak pathway inhibition a novel treatment strategy |
| topic | COVID-19 JAK inhibitors baricitinib pacritinib ruxolitinib tofacitinib |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.961027/full |
| work_keys_str_mv | AT mansoorkhaledi covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT fatemehsameni covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT sheidayahyazade covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT maedehradandish covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT parvizowlia covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT naderbagheri covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT hamedafkhami covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT mohamadmahjoor covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT zahraesmaelpour covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT maryamkohansal covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy AT farzadaghaei covid19andthepotentialofjanusfamilykinasejakpathwayinhibitionanoveltreatmentstrategy |